Krill oil may benefit obese individuals by counteracting effects on the endocannabinoid system.
A new preclinical trial on mice published in Nutrition & Metabolism indicates that krill oil may benefit obese individuals by counteracting effects on the endocannabinoid system.
Mice were fed a high-fat diet with or without three different doses of krill oil. As opposed to the low-fat diet, a high-fat diet resulted in elevation of endocannabinoids (EC), which are lipid messengers that can activate specific receptors, thereby influencing enzyme activities as well as appetite, energy balance, mood, memory, and pain perception. EC supposedly thus helps to contribute to accumulation of visceral fat.
Aker BioMarine, which markets the Superba-brand krill oil used in the study, says that krill oil counteracted the changes in EC levels caused by the high-fat diet, after eight weeks of treatment. In addition, it exerted lowering effects on triglycerides and cholesterol.
Aker BioMarine says that it is now initiating a clinical study to further examine the potential benefits of krill oil for obese subjects.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.